|Mutations associated with acquired resistance to PD-1 blockade in melanoma|
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
|Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma|
W Hugo, JM Zaretsky, L Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
|Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy|
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery 4 (1), 80-93, 2014
|Primary resistance to PD-1 blockade mediated by JAK1/2 mutations|
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
|Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression|
A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ...
Cell Reports 19 (6), 1189-1201, 2017
|Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma|
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5, 5712, 2014
|Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance|
W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
|Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma|
TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ...
Nature medicine 25 (3), 477, 2019
|Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction|
G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ...
Cancer cell 27 (2), 240-256, 2015
|Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms|
DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ...
European Journal of Cancer 51 (18), 2792-2799, 2015
|Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis|
TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ...
Cancer discovery 4 (4), 423-433, 2014
|A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition|
H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ...
Cancer discovery 4 (1), 69-79, 2014
|Regional Glutamine Deficiency in Tumours Promotes De-differentiation through Inhibition of Histone Demethylation|
M Pan, MA Reid, XH Lowman, RP Kulkarni, TQ Tran, X Liu, Y Yang, ...
Nature cell biology 18 (10), 1090, 2016
|Recurrent tumor cell-intrinsic and-extrinsic alterations during MAPKi-induced melanoma regression and early adaptation|
C Song, M Piva, L Sun, A Hong, G Moriceau, X Kong, H Zhang, S Lomeli, ...
Cancer Discovery, CD-17-0401, 2017
|Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors|
AA Marusiak, ZC Edwards, W Hugo, EW Trotter, MR Girotti, ...
Nature communications 5, 2014
|A correlated motif approach for finding short linear motifs from protein interaction networks|
SH Tan, W Hugo, WK Sung, SK Ng
BMC bioinformatics 7 (1), 502, 2006
|JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma|
B Titz, A Lomova, A Le, W Hugo, X Kong, J Ten Hoeve, M Friedman, H Shi, ...
Cell Discovery 2, 16028, 2016
|Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma|
A Hong, G Moriceau, L Sun, S Lomeli, M Piva, R Damoiseaux, SL Holmen, ...
Cancer Discovery, CD-17-0682, 2017
|Stringent DDI-based prediction of H. sapiens-M. tuberculosis H37Rv protein-protein interactions|
H Zhou, J Rezaei, W Hugo, S Gao, J Jin, M Fan, CH Yong, M Wozniak, ...
BMC systems biology 7 (6), S6, 2013
|Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors|
H Escuin-Ordinas, S Li, MW Xie, L Sun, W Hugo, RR Huang, J Jiao, ...
Nature Communications 7, 2016